The progress of cell-replacement therapy for age-related macular degeneration
10.3760/cma.j.issn.1005-1015.2016.01.026
- VernacularTitle:老年性黄斑变性视网膜色素上皮细胞替代治疗研究进展
- Author:
Han SHEN
;
Qinghuai LIU
;
Songtao YUAN
- Publication Type:Journal Article
- Keywords:
Macular degeneration/therapy;
Retinal pigment epithelium;
Cell transplantation;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2016;32(1):92-96
- CountryChina
- Language:Chinese
-
Abstract:
Based on the pathogenic mechanisms of age-related macular degeneration (AMD),tremendous preclinical and clinical trials have demonstrated that cell transplantation which aim to replace impaired retinal pigment epithelium (RPE) with healthy RPE cells is a promising approach to treat AMD.So far,choices of cell sources mainly are autologous RPE,iris pigment epithelium,fetal RPE,human embryonic stem cell-derived RPE and human induced pluripotent stem cell-derived RPE,and some of them are undergoing clinical researches.Grafting manners in cell-based therapies are various including RPE sheet or RPE-choroid complex transplantation,RPE cell suspension injection,and RPE sheet transplantation with scaffolds.This review is limited to cell-based therapies for RPE that damaged first in the progress of AMD and focus on recent advances in cell sources,transplantation methods,preclinical and clinical trials,and the obstacles that must be overcome.
